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Abstract Dystrophic skeletal muscle cells from Duchenne
muscular dystrophy (DMD) patients and mdx mice exhibit
elevated cytosolic Ca2+ concentrations ([Ca2+]c). Pretreatment of
mdx myotubes for 6^12 days with creatine (20 mM) decreased
the elevation in [Ca2+]c induced by either high extracellular Ca
2+
concentrations or hypo-osmotic stress to control levels. 45Ca2+
influx measurements suggest that creatine lowered [Ca2+]c by
stimulating sarcoplasmic reticulum Ca2+-ATPase. Creatine
pretreatment increased levels of phosphocreatine but not ATP.
Furthermore, myotube formation and survival were significantly
enhanced by creatine pretreatment. Therefore, creatine supple-
mentation may be useful for treatment of DMD.
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1. Introduction
Duchenne muscular dystrophy (DMD) is a severe degener-
ative muscle disease caused by a mutation in the dystrophin
gene, located on chromosome Xp21. Dystrophin is associated
with a complex of transmembrane glycoproteins, the dystro-
phin-glycoprotein complex, and acts as a transsarcolemmal
linker between the subsarcolemmal cytoskeleton and the ex-
tracellular matrix [1^4]. Loss of this complex results in me-
chanical instability of the sarcolemma [5], rendering dystro-
phic muscle more susceptible to stress [6,7] resulting in an
increased activity of ‘leak’ [8,9], and/or stretch-inactivated
Ca2 channels [10^13]. The subsequent elevation of cytosolic
calcium concentrations ([Ca2]c) triggers Ca2-activated pro-
teases such as calpain, further increasing the activity of cal-
pain-sensitive Ca2-leak channels [14] and decreasing the
function of calpain-sensitive plasma membrane Ca2-ATPases
[15], which in turn leads to a cascade of Ca2-dependent ca-
tabolic events [16,17]. Denetclaw et al. have shown that trans-
genic introduction of dystrophin into mdx myotubes recovers
[Ca2]c and open probabilities of Ca2-leak channels to nor-
mal levels [18], emphasizing the e¡ect of dystrophin on cyto-
solic Ca2 regulation.
Several enzyme systems, Ca2-speci¢c pumps and ion chan-
nels are known to work together to maintain tight control of
[Ca2]c. One of these enzymes, creatine kinase (EC 2.7.3.2,
CK), provides energy for the calcium-sequestering sarcoplas-
mic reticulum (SR) Ca2-ATPase and catalyzes the reversible
transphosphorylation of the high energy N-phosphoryl group
of phosphocreatine (PCr) to ADP, regenerating ATP by the
following reaction [19] :
MgADP3  PCr23 H CK!MgATP23  Cr
CK is expressed in a tissue-speci¢c manner and is highly
compartmentalized with an additional mitochondrial isoform
(Mi-CK) [20]. The muscle-type MM-CK is localized in the
vicinity of the SR Ca2-ATPase [21,22] which preferentially
utilizes ATP generated by CK [23] and is therefore critically
involved in controlling [Ca2]c homeostasis [19]. Inhibition of
SR-bound CK has been shown to lead to a drastic decrease in
SR Ca2 uptake [21] and transgenic mice devoid of both
muscle CK isoenzymes display serious problems with muscle
relaxation due to elevated [Ca2]c [24].
Cellular creatine uptake is achieved by the speci¢c creatine
transporter protein (CreaT) in a sodium- and chloride-de-
pendent process, which moves creatine against a concentra-
tion gradient [25]. CreaT is expressed in several tissues, includ-
ing skeletal muscle [26].
Using dystrophic skeletal muscle cells from the mdx mouse
model of DMD, we and others have demonstrated impaired
[Ca2]c regulation in response to hypo-osmotic and high ex-
tracellular calcium ([Ca2]extrac) stress [6,7]. With the aim of
counteracting these stress-induced increases in [Ca2]c, we
have earlier examined the e¡ects of prolonged administration
of steroid hormones such as K-methylprednisolone (PDN)
[7,26]. Our current results show that creatine increases cellular
PCr levels and improves the regulation of [Ca2]c in mdx
myotubes exposed to stress. In addition, increased myotube
formation and cell survival was observed. To our knowledge,
these data are the ¢rst to show that creatine supplementation
acts to lower [Ca2]c and enhances survival of dystrophic
skeletal muscle cells.
2. Materials and methods
2.1. Cell cultures
Primary cell cultures of mouse skeletal muscle cells were prepared
from hind leg muscles of 1^4-day-old normal (C57BL/10) and mdx
mice as described [27]. Cells were seeded at 5U104 cells/cm2 in me-
dium 199 (Gibco, Basel, Switzerland) containing 10% horse serum
(Gibco) either on glass coverslips (9U18 mm) for [Ca2]c measure-
ments or in 24-well polystyrene plates coated with 2% gelatin (Sigma,
Buchs, Switzerland) for £ux experiments. Fusion of myoblasts into
myotubes occurred at day 3 in culture and was completed within
the next 24 h.
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2.2. Culture treatment
K-Methylprednisolone (1036 M, Upjohn Pharma, Bruºttisellen, Swit-
zerland) and creatine (20 mM, Sigma, Buchs, Switzerland) were added
at the beginning of myoblast fusion (day 3 of culture) [7]. Fresh
medium was added after 5 days in culture. Myotubes were used for
the experiments between days 12 and 14 in culture.
2.3. Measurements of the cytosolic calcium concentration
[Ca2]c measurements were performed on single Fura-2-loaded
myotubes, as described previously [7]. Cells cultured on a glass cover-
slip were washed twice with control PSS bu¡er (Table 1) and incu-
bated for 30 min with Fura-2/AM (5 WM) (Molecular Probes, Eugene,
OR, USA) in control PSS bu¡er. The coverslip was analyzed in a
thermostatted chamber (37‡C) on a Nikon Diaphot inverted epi£uor-
escence microscope, with a PhoCal single cell £uorescence analyzer
(Life Science Resources, Cambridge, UK). The myotubes were illumi-
nated with alternating light of 340 and 380 nm from a rotating ¢lter
wheel (6.25 Hz). Emission was monitored at 510 nm. Results are given
as calculated [Ca2]c as described [28].
2.4. Experimental protocols
In order to examine changes in [Ca2]c due to hypo-osmotic or high
[Ca2]extrac stress, myotubes were exposed to two types of extracellular
shock (100 mOsm, bu¡er 2, and 40 mM [Ca2]extrac, bu¡er 1, see
Table 1). The following protocol was used: control bu¡er (5 min) ^
100 mOsm bu¡er (bu¡er 2) (10 min) ^ control bu¡er (5 min) ^ 40 mM
CaCl2 (bu¡er 1) (2 min) ^ control bu¡er (10 min) ^ calibration pro-
cedure [7]. The myotubes were also examined in the opposite se-
quence: control bu¡er (5 min) ^ bu¡er 1 (2 min) ^ control bu¡er
(5 min) ^ bu¡er 2 (10 min) ^ control bu¡er (10 min) ^ calibration
procedure. The osmolarity was determined by measuring the lowering
of the freezing point (Osmometer, Infochroma, Zug, Switzerland).
2.5. 45Ca2+ in£ux assay
45Ca2 (from Amersham-Rahn, Zuºrich, Switzerland) in£ux meas-
urements were performed as previously described [29]. Brie£y, myo-
tubes were preincubated for 10 min in control bu¡er (Table 1) con-
taining 0.12 mM CaCl2. Basal in£ux was determined by exposing the
myotubes to 0.2 ml of control bu¡er containing 1.2 mM CaCl2 and
0.4 WCi of 45Ca2. Hypo-osmotic and high [Ca2]extrac in£ux was
determined by incubating myotubes for 15 min with 0.2 ml of the
appropriate experimental bu¡er containing 0.4 WCi (bu¡er 2) or
1.6 WCi (for high [Ca2]extrac assay, bu¡er 3) of 45Ca2. In£ux was
stopped with EGTA (2 mM) and cells were lysed with trypsin (0.25%)
and sodium dodecyl sulfate (1%). Radioactivity was determined by
scintillation counting (Packard 460C, Zuºrich, Switzerland). Protein
measurements were performed as described [7].
2.6. Determination of myotube numbers and survival
Myotubes were stained with May-Gruºnwald-Giemsa stain and
counted as previously described [27]. Myotube survival was deter-
mined by trypan blue assay. Five randomly chosen ¢elds were counted
per dish and three dishes were examined for each condition.
2.7. ATP and phosphocreatine measurements
ATP and PCr levels were measured as previously described [30].
Luciferin and luciferase were purchased from Molecular Probes.
Hypo-osmotic (bu¡er 2) and high [Ca2]extrac (bu¡er 1) shock were
applied to 12-day-old myotubes grown in 24-well plates and treated
with 20 mM creatine from day 3. Trichloroacetic acid (10%) at 0‡C
was used to extract ATP and PCr and was washed out with saturated
ether. Luminescence was recorded on an ML 3000 plate reader (Dy-
natech, Embrach, Switzerland) for ATP and an LKB 410 luminom-
eter (LKB-Pharmacia, Uppsala, Sweden) for PCr.
2.8. Statistics
All values are expressed as mean þ S.E.M., with the exception of
Fig. 4 where S.D. was used. Student’s t-test was used for statistical
analysis.
3. Results
We have previously shown that exposure of myotubes to
hypo-osmotic solution (100 mOsm) or bu¡er with increased
extracellular Ca2 concentrations results in a transient rise
in [Ca2]c, which is more pronounced in mdx myotubes
than in controls [7]. Values for [Ca2]c for both mdx and
C57BL/10 myotubes under these stress conditions are shown
in Fig. 1.
3.1. E¡ect of creatine supplementation on hypo-osmotic
stress-induced increases in [Ca2+]c
Following the onset of myotube formation (day 3 after
seeding), the cultures were incubated for 9^11 days with crea-
tine (20 mM). As a positive control, K-methylprednisolone
(PDN, 1036 M), which has been shown to inhibit stress-in-
duced increases in [Ca2]c [7], was added to parallel cultures.
Neither creatine nor PDN pretreatment had a signi¢cant ef-
fect on basal [Ca2]c in mdx or control C57BL/10 myotubes
(Fig. 1). Exposure of mdx myotubes to hypo-osmotic shock
resulted in an increased [Ca2]c within 2^10 min. Creatine
(20 mM) pretreatment attenuated this increase and restored
levels close to basal values (from 118 þ 12 nM to 62 þ 17 nM,
P6 0.001) as did PDN (Fig. 1B).
3.2. E¡ect of creatine on high [Ca2+]extrac stress-induced
increases in [Ca2+]c
Superfusion of myotubes with bu¡er 1 containing 40 mM
[Ca2]extrac more than doubled [Ca2]c in mdx myotubes, rel-
ative to untreated mdx and control C57BL/10 myotubes (Fig.
1). Pretreatment with 20 mM creatine inhibited this increase
in [Ca2]c (from 112 þ 15 nM to 59 þ 17 nM, P6 0.001) to
levels similar to control values, and to the same extent as
PDN (Fig. 1B). In contrast to that elicited by hypo-osmotic
shock, the high [Ca2]extrac-induced increases in [Ca2]c in
control C57BL/10 myotubes were slightly reduced by creatine
pretreatment (Fig. 1A).
3.3. E¡ects of creatine supplementation on stress-induced
45Ca2+ in£ux
Under both conditions of stress, Ca2 in£ux more than
doubled in mdx myotubes, while in control C57BL/10 myo-
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Table 1
Composition of experimental bu¡ers
Control bu¡er (PSS) Bu¡er 1 (high Ca2) Bu¡er 2 (low osm) Bu¡er 3 (high Ca2)
HEPES 5 5 5 5
KCl 5 5 5 5
MgCl2 1 1 1 1
NaCl 145 85 6 135
CaCl2 1.2 40 1.2 10
Glucose 10 10 1 10
Sucrose ^ ^ 50 ^
Osmolarity (mOsm) 300 308 100 300
All bu¡ers were at pH 7.4.
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tubes a milder increase was noted (Fig. 2). In control myo-
tubes, creatine and PDN produced a reduction of Ca2 in£ux
when myotubes were exposed to high [Ca2]extrac (Fig. 2A).
In contrast, in mdx myotubes creatine pretreatment did not
a¡ect stress-induced Ca2 in£ux while PDN was e¡ective (Fig.
2B).
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Fig. 1. E¡ects of creatine and PDN on [Ca2]c changes in control C57BL/10 (A) or mdx myotubes (B). Myotubes (day 12^14) were exposed to
hypo-osmotic shock (bu¡er 2) or high [Ca2]extrac (bu¡er 1) as described in Section 2. Untreated myotubes (open columns), myotubes pre-
treated with creatine (20 mM, gray columns), myotubes pretreated with PDN (1036 M, black columns). Five experiments from three separate
primary cultures were performed in duplicate. Asterisks indicate signi¢cantly di¡erent values (*P6 0.01, **P6 0.001, Student’s t-test). ns: not
signi¢cant.
Fig. 2. E¡ects of creatine and PDN on 45Ca2 in£ux in C57BL/10 (A) or mdx (B) myotubes. Untreated myotubes (open columns), myotubes
pretreated with creatine (20 mM, gray columns), myotubes pretreated with PDN (1036 M, black columns). Both agents were added on day 3
of culture, and 45Ca2 in£ux was measured at day 12, as described in Section 2. Three experiments from separate primary cultures were each
performed in quadruplicate. Asterisks indicate signi¢cantly di¡erent values (*P6 0.01, Student’s t-test), compared to control.
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3.4. Time course of creatine supplementation on stress-induced
increases in [Ca2+]c
The cultures were incubated for 1^12 days after seeding
with 20 mM creatine and the e¡ect of hypo-osmotic or high
[Ca2]extrac stress on [Ca2]c was then determined. Pretreat-
ment for at least 6 days before the experiment inhibited the
increase in [Ca2]c due to stress (Fig. 3). No e¡ect was ob-
served if creatine was added to myotubes for shorter periods
before the experiment or acutely, 5 min to 1 h prior to meas-
urement (data not shown).
3.5. Creatine enhances di¡erentiation, myotube number and
survival in mdx and C57BL/10 cultures
The numbers of multinucleated myotubes in skeletal muscle
cell cultures from mdx and C57BL/10 cells (after 7- or 11-day
pretreatment with either creatine or PDN) were determined as
described in Section 2, at days 10 and 14 of culture. The
results (Table 2) show that myotube numbers in mdx cultures
were increased 4^6-fold after pretreatment with creatine or
with PDN. Both agents had similar e¡ects on C57BL/10 cul-
tures, but to a smaller extent (2^4-fold increase, Table 2).
Creatine-treated mdx cultures exhibited more myotube
branching and an increase in size relative to untreated mdx
or control cultures. Increased myotube survival was apparent
up to 17 days after creatine pretreatment and percentages of
trypan blue-positive cells were markedly decreased in creatine-
treated versus untreated controls (data not shown).
3.6. ATP and phosphocreatine measurements in mdx and
C57BL/10 myotubes exposed to stress
ATP levels in mdx or C57BL/10 myotubes were not signi¢-
cantly di¡erent from each other and were not a¡ected by
either stress treatment resulting in ratios close to 1 (Table
3). In contrast, PCr levels in mdx myotubes were about half
of those in controls, and high [Ca2]extrac, but not hypo-os-
motic shock, decreased these further (Table 3). Supplementa-
tion with 20 mM creatine increased PCr levels in both control
and mdx cells (Table 3, Fig. 4), this e¡ect being even more
pronounced in mdx cells (Fig. 4).
4. Discussion
Calcium homeostasis in dystrophin de¢cient skeletal muscle
cells derived from DMD patients and mdx mice has been
shown to be dysfunctional, leading to a chronic Ca2 over-
load [9,11,12,14,31^34]. We have exposed mdx and C57BL/10
control myotubes to reduced osmolarity or high [Ca2]extrac,
and have found increases in [Ca2]c (Fig. 1) as well as in
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Table 2
Creatine increases myotube numbers in C57BL/10 and mdx-derived skeletal muscle cultures
Mouse strain Day Myotubes/¢eld
Control 20 mM CR 1 WM PDN
C57BL/10 10 10.3 þ 1.99 24.3 þ 1.27 20.6 þ 2.99
14 6.3 þ 1.11 23.2 þ 1,39 193. þ 1.56
mdx 10 8.6 þ 1.13 38.6 þ 1.26 35.1 þ 2.85
14 6.6 þ 1.14 39.2 þ 1.66 34.3 þ 1.89
Analyses were performed as described in Section 2.
Fig. 3. Time course of creatine e¡ect on [Ca2]c increases elicited by
stress in mdx myotubes. Myotubes (day 13) were exposed to basal
conditions (a, control bu¡er), hypo-osmotic shock (b, bu¡er 2) or
high [Ca2]extrac (8, bu¡er 1) as described in Section 2. Creatine
(20 mM) was added to the cultures for the periods indicated before
[Ca2]c measurements on day 13. Five experiments from three sepa-
rate primary cultures were performed in duplicate. Asterisks indicate
signi¢cantly di¡erent values (**P6 0.001, Student’s t-test), com-
pared to control.
Fig. 4. E¡ects of creatine pretreatment on cellular PCr levels. Myo-
tubes were prepared and PCr was measured as described in Section
2. Results are expressed as ratios of creatine-pretreated versus un-
treated C57BL/10 (open columns) or mdx (hatched columns) myo-
tubes exposed to stress protocols. Asterisks indicate signi¢cantly dif-
ferent values (*P6 0.01, **P6 0.001, Student’s t-test).
S.M. Pulido et al./FEBS Letters 439 (1998) 357^362360
45Ca2 in£ux (Fig. 2) in mdx but not in control myotubes.
This is consistent with an increase in stretch or ‘leak’ Ca2
channel activity [6,9]. Chronically elevated [Ca2]c is known
to cause activation of Ca2-dependent proteases (e.g. the cal-
pains), which in turn can increase Ca2 leak channel activity
[14], reduce mitochondrial function (and therefore ATP syn-
thesis) and eventually lead to muscle cell apoptosis or necrosis
[35].
The hypo-osmotic or hypercalcemic stress-induced increases
in [Ca2]c in mdx myotubes were signi¢cantly inhibited by
several days of pretreatment with creatine (Fig. 1). The extent
of inhibition was comparable to that which we have previ-
ously reported for the glucocorticoid PDN or other steroids
[7,27]. This e¡ect of creatine could be due to a decrease in
sarcolemmal (SL) leak channel-mediated Ca2 in£ux, or to
improved sarcoplasmic (SR) uptake of cytosolic calcium. Cre-
atine pretreatment of mdx myotubes did, however, not a¡ect
the stress-induced increase in 45Ca2 in£ux (Fig. 2), thus rul-
ing out that creatine a¡ected cellular Ca2 entry. An e¡ect on
the SL Ca2 ATPase or on the SR Ca2-ATPase is likely.
Stimulation of the SL Ca2 ATPase would lead to increased
cellular Ca2 extrusion and of the SR Ca2 ATPase to in-
creased Ca2 sequestration. As 45Ca2 e¥ux was not altered
by creatine treatment (our own unpublished observations), an
e¡ect on the SL Ca2 ATPase can be ruled out and the SR
Ca2 pump is the most likely target for creatine action. Such
an e¡ect would lead to a more e⁄cient SR Ca2 uptake which
would not alter total cellular 45Ca2 in£ux, which is what was
observed (Fig. 2B).
The direct coupling of creatine kinase (CK) to the SR Ca2-
ATPase, the energetically most highly demanding Ca2 pump
in muscle [21], has been shown to convey a functional and
kinetic advantage for Ca2 sequestration [21^23]. The SR
Ca2 pump derives its ATP preferentially from PCr via the
SR-bound CK which leads locally to a very high ATP/ADP
ratio [36]. The crucial involvement of SR-bound CK in Ca2
homeostasis of skeletal muscle has been corroborated by the
phenotype of CK null-mutant transgenic mice which have
severe problems in calcium handling and relaxation of their
skeletal muscles and which overproduce as a compensatory
measure a grossly enlarged tubular SR membrane network
[24].
Mdx cells showed a reduced PCr content and long-term
creatine exposure led to increased PCr levels (Table 3). These
results are consistent with those previously reported which
demonstrate similar ATP levels but decreased PCr levels in
human and murine dystrophic muscles relative to control [37].
One way that elevated [PCr] could lead to long term meta-
bolic changes is by preventing the activation of the AMP-
dependent protein kinase. This enzyme, which has recently
been shown not only to be regulated by the ATP/AMP ratio,
but also by the PCr/Cr ratio [38] can speci¢cally phosphoryl-
ate CK downregulating its activity [38]. Therefore, increasing
the cellular PCr levels by creatine supplementation, should
increase the local ATP concentrations, and this is bound to
lower ADP and even more so AMP concentrations [19]. These
combined events, higher PCr and lower AMP levels, would
keep the AMP-dependent protein kinase inactive [38], thus
preventing the downregulation of CK activity [35]. Taken to-
gether, creatine supplementation should increase the availabil-
ity of PCr for an active form of the SR-bound CK, which
increases the local supply of the SR-Ca2 pump with ATP
and consequently the e⁄ciency of Ca2 sequestration [35].
In addition to this energy-donating e¡ect of creatine, it has
recently been shown that binding of creatine to the mitochon-
drial isoform of CK directly inhibits the formation of the
mitochondrial permeability transition pore, thus inhibiting
apoptosis [35].
Production of new myotubes is dependent on the rapid
production and fusion of myoblasts and/or satellite cells,
which is an energy and calcium requiring process. Creatine-
treated mdx and C57BL/10 cultures were found to exhibit a
greater number of myotubes, an elevated degree of branching,
and an increase in size relative to untreated control myotube
cultures (Table 2). Creatine also increased mdx and C57BL/10
myotube viability, extending the life of primary cells in culture
to 20 days. We hypothesize that adding creatine at the time of
fusion of the myoblasts provides energy for dystrophic cells
and prevents an accumulation of Ca2 in the cytoplasm. Due
to an increased in£ux of Ca2 into dystrophic myotubes, the
Ca2-ATPases may be functioning at a higher rate during
di¡erentiation, relative to control cells. The energy provided
by the increased PCr could be used continuously to regulate
cytosolic Ca2 levels during fusion and di¡erentiation and
may reduce the activity of Ca2-activated proteases and
thus reduce membrane instability and further Ca2 leakage.
Oral supplementation with creatine has been shown, in nor-
mal subjects, to lead to elevated levels of both total creatine
and phosphocreatine in muscles, thereby improving the cellu-
lar energy status and muscle performance and recovery fol-
lowing strenuous exercise [39]. Based on our results, showing
a marked improvement in mdx muscle cell survival and Ca2
homeostasis, especially after stress, and on preliminary ¢nd-
ings with patients with neuromuscular diseases [40,41] we pro-
pose that creatine is a substance with potential therapeutic
properties which should be investigated as a possible adjuvant
to established therapies [42].
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Table 3
E¡ect of creatine on ATP and PCr ratio (mdx/C57BL/10) under basal or stress conditions
mdx/C57BL/10 ration ( þ S.D.)
untreated Creatine (20 mM)
ATP PCr ATP PCr
Basal conditions 0.98 þ 0.02 0.46 þ 0.02 0.92 þ 0.05 0.61 þ 0.08
Osmotic shock 0.91 þ 0.02 0.42 þ 0.05 0.93 þ 0.06 0.81 þ 0.01
High [Ca2]extrac 0.90 þ 0.25 0.33 þ 0.01 0.91 þ 0.12 0.65 þ 0.11
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